Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, completed the second phase of a $5.5 million expansion program at its facility in Kansas City, Missouri. The expansion will increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.

According to company officials, this marks the conclusion of a two-year project that has also expanded the facility’s highly-potent, cytotoxic and cold storage clinical drug packaging capabilities.

The latest expansion includes a new Drug Enforcement Administration Schedule I and II controlled substance vault, providing the site with an additional 3,600 square feet of storage, company officials explained; The expansion includes additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations. A new sampling room has been installed, as well as a new emergency generator to ensure the security and integrity of samples in storage.

“Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years,” commented Kevin Economos, General Manager of Clinical Supply Services at the site. “These latest expansions are critical enablers to our customers’ continued growth, that reinforce our comprehensive global network, and enhance Catalent’s role as a market leader in the clinical supply industry.”

Catalent said its 450,000-square feet Kansas City facility provides a range of fully integrated support services, from development and analytical support through to packaging and distribution. The expansions at Kansas City follow the recent announcements of new capabilities and capacity at two of Catalent’s other clinical supply facilities in Philadelphia and Singapore.